Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hitting cancer where it hurts

K Sunassee1, R Vile

  • 1ICRF Laboratory of Molecular Therapy, ICRF Oncology Unit, Hammersmith Hospital, DuCane Road, London, W12 ONN, UK.

Current Biology : CB
|May 1, 1997
PubMed
Summary

New anti-cancer therapies emerge from targeting tumor blood supply. Studies demonstrate tumor-specific blood clots via molecular engineering and identify endostatin, a natural tumor matrix inhibitor, offering dual hope for treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The epidemiology of injury and illness amongst athletes at the Indian Ocean Island Games, Mauritius, 2019.

South African journal of sports medicine·2023
Same author

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.

Gene therapy·2016
Same author

In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery.

Journal of controlled release : official journal of the Controlled Release Society·2015
Same author

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

International journal of cancer·2013
Same author

Histological findings of birdshot chorioretinopathy in an eye with ciliochoroidal melanoma.

Eye (London, England)·2012
Same author

Measles virus causes immunogenic cell death in human melanoma.

Gene therapy·2011

Area of Science:

  • Oncology
  • Vascular Biology
  • Biotechnology

Background:

  • Tumor blood supply is crucial for cancer growth and metastasis.
  • Targeting tumor vasculature is a promising anti-cancer strategy.
  • Recent advancements offer novel approaches to disrupt tumor angiogenesis and perfusion.

Purpose of the Study:

  • To explore innovative strategies for anti-cancer therapies by targeting tumor blood supply.
  • To present findings on molecular engineering for tumor-specific thrombosis.
  • To highlight the potential of natural inhibitors like endostatin in cancer treatment.

Main Methods:

  • Molecular engineering techniques to induce tumor-specific blood clots.
  • Identification and characterization of endostatin from tumor extracellular matrix.
  • Analysis of the anti-tumor effects of these novel therapeutic approaches.

Main Results:

  • Successful induction of tumor-specific blood clots using advanced molecular engineering.
  • Identification of endostatin as a naturally occurring inhibitor with potential anti-cancer properties.
  • Demonstration of promising outcomes in preclinical models targeting tumor vasculature.

Conclusions:

  • Perturbing tumor blood supply presents a viable and hopeful avenue for novel anti-cancer therapies.
  • Tumor-specific thrombosis and the use of natural inhibitors like endostatin represent significant progress.
  • These findings pave the way for the development of more effective cancer treatments.

Related Experiment Videos